Recon: Infant formula recalled for potential contamination risks; Bristol Myers to acquire cancer startup RayzeBio for $4.1B

• Reckitt's Mead Johnson Nutrition recalls baby formula powder from US (Reuters) (CBSnews) (FDA)
• Zealand drug hit with CRL for ultra-rare disease amid manufacturing concerns, plans to resubmit in 2024 (Endpoints)
• FDA declines to grant Amgen’s Lumakras full approval in lung cancer after negative advisory committee vote (Endpoints)
• Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti (Endpoints)
• Iovance’s registrational lung cancer trial on hold after patient death (Endpoints)
• FDA seizes thousands of counterfeit Ozempic units, warns consumers not to use (Endpoints)
• Big Totals And Big Margins: US FDA Approved 72 Novel Agents In 2023 – And Acted On 90+ (Pink Sheet)
• The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now (Pink Sheet)
• Drug-Drug Interactions: Future FDA Guidance Will Focus On Specific Modalities; Patient Website To Come (Pink Sheet)
• Exclusive: Drugmakers set to raise US prices on at least 500 drugs in January (Reuters)
• MiMedx Falls on FDA Warning Letter For Axiofill Classification (Bloomberg)

• AstraZeneca, Sanofi RSV infant shots approved in China (Reuters)
• UK’s New International Recognition Procedure A ‘Win-Win’ For Stakeholders (Pink Sheet)
• New Canadian Drug Agency To Focus On Drug Access & Affordability (Pink Sheet)
• EMA Homes In On Bacteriophages In Fight Against AMR (Pink Sheet)
• EU CHMP Opinions And MAA Updates (Pink Sheet)
• Brazil Aims For Top 10 Spot In Clinical Research (Pink Sheet)

• Bristol Myers will pay $4.1 billion for cancer startup RayzeBio (STAT)
• Novartis Inks Potential $1.3B Gene Therapy Deal with Voyager to Target Neuro (Biospace)
• AstraZeneca makes $1B deal for Gracell and its cell therapies, adding to China ties (Endpoints)
• ImmunityBio Snags $320M Royalty Deal Ahead of FDA Decision in April (Biospace)
• Regeneron scores Eylea patent win against Mylan, keeping biosimilar at bay (Endpoints)
• Cytokinetics heart drug aficamten succeeds in pivotal study (STAT) 

• Shunned by insurers, digital therapeutics startups look for other ways to get paid (Endpoints)
• Roche to buy part of LumiraDx diagnostics platform for $295 million (Reuters)
• Apple Watches Are Back On The US Market (MedTech Dive) 
• Philips pays $2.4 million for allegedly giving kickbacks to sleep labs (STAT)
• Former Stimwave CEO Charged With Securities Fraud (MedTech Insight) 

• US judge allows FTC to temporarily block IQVIA acquisition of DeepIntent (Reuters)
• LumiraDx Appoints Administrators, Sells Platform to Roche (Bloomberg)
• McKinsey to pay $78 million in US opioid settlement with health plans (Reuters)
• LumiraDx Appoints Administrators, Sells Platform to Roche (Bloomberg)
• Abortion, Guns, Jan. 6 Highlight Top Supreme Court Cases in 2024 (Bloomberg)